Acquisition (action)
Novo Nordisk Acquires Mid-Stage Heart Failure Biotech Cardior for Up to $1.1 Billion
Novo Nordisk, Cardior Pharmaceuticals, Heart Failure Biotech, Acquisition, $1.1 billion
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk
Holdings, Nordisk, deal, Acquisition (action), Investments
Sanofi gains AATD hopeful with $1.7-billion deal for Inhibrx
sanofi, Inhibrx, Acquisition (action), alpha 1-Antitrypsin Deficiency, Market